search
Back to results

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Primary Purpose

B Cell Lymphoma

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
CD20-directed CAR-T cells
Sponsored by
Shanghai Tongji Hospital, Tongji University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for B Cell Lymphoma focused on measuring B cell lymphoma received prior CD19 CAR-T therapy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Volunteered to participate in this study and signed informed consent
  2. Age 14-70 years old, male or female
  3. Patients with CD20+ DLBCL(including PMBL and according to the NCCN. non Hodgkin's lymphoma Guidelines(2019 version1.0) , at least one measurable lesion(LDi≥ 1.5 cm);
  4. r/r patients who received prior CD19 CAR-T therapy;
  5. At least one week from the end of treatment regimen (radiation, chemotherapy, mAb, etc) to apheresis;
  6. No immunosuppressive therapy was used within 1 week before infusion, including but not limited to systemic therapy;
  7. No mAb treatment within 2 weeks before infusion
  8. LVEF≥ 50% (UCG)
  9. No active pulmonary infections, normal pulmonary function and SpO2≥92%
  10. No contraindications of apheresis;
  11. Expected survival ≥ 3months
  12. ECOG score 0 or 1
  13. The apheresis was received by laboratory and met the requirements for manufacturing CAR-T cell

Exclusion Criteria:

  1. Have a history of allergy to cellular products
  2. Laboratory criteria: Serum total bilirubin ≥2mg/dl, albumin≤35g/L, AST and ALT ≥5 x ULN, Creatinine≥2.0mg/dl, ANC≤750/uL, Platelets≤ 50x10^9/L
  3. Have a hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome ,etc;
  4. According to the NYHA cardiac function grading standards, patients with grade III or IV cardiac dysfunction;
  5. A history of QT prolongation
  6. Patients with central nervous system involvement
  7. Severe active infections (except for simple urinary tract infections, bacterial pharyngitis), or currently undergoing intravenous infusion of antibiotics, or intravenous infusion of antibiotics within 1 week prior to cell infusion. However, prophylactic antibiotic, antiviral and antifungal infection treatments are permissible;
  8. People infected with HIV, HBV, HCV and TPPA/RPR, and carriers with HBV;
  9. Subjects who are not sterilized have any of the following conditions:

    1. are pregnant/lactating; or
    2. planned pregnancy during the trial; or
    3. being fertile and unable to use effective contraception;
  10. The investigators consider that the subject has other conditions that are not suitable for this trial.

Sites / Locations

  • Shanghai Tongji Hospital, Tongji University School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

C-CAR066

Arm Description

Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion

Outcomes

Primary Outcome Measures

Incidence of adverse events
The incidence of treatment-emergent adverse events (TEAEs)

Secondary Outcome Measures

Objective response rate (ORR)
The percentage of subjects who achieved complete response and partial response
Complete response rate (CRR)
The percentage of subjects who achieved complete response
Duration of response (DOR)
The time from the date of first response (PR or CR) to the date of disease progression or death after C-CAR066 infusion
Progression free survival (PFS)
The time from C-CAR066 infusion to the date of progression as assessed by Lugano 2014 criteria or death
Overall survival (OS)
Time from C-CAR066 infusion to death from any cause

Full Information

First Posted
July 8, 2019
Last Updated
July 17, 2023
Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborators
Cellular Biomedicine Group Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04036019
Brief Title
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Official Title
A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
May 28, 2019 (Actual)
Primary Completion Date
June 20, 2022 (Actual)
Study Completion Date
June 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborators
Cellular Biomedicine Group Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.
Detailed Description
This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection. The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
B Cell Lymphoma
Keywords
B cell lymphoma received prior CD19 CAR-T therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
C-CAR066
Arm Type
Experimental
Arm Description
Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
Intervention Type
Biological
Intervention Name(s)
CD20-directed CAR-T cells
Other Intervention Name(s)
C-CAR066
Intervention Description
Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
Primary Outcome Measure Information:
Title
Incidence of adverse events
Description
The incidence of treatment-emergent adverse events (TEAEs)
Time Frame
Up to 12 weeks after C-CAR066 infusion
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
The percentage of subjects who achieved complete response and partial response
Time Frame
Up to 24 months after C-CAR066 infusion
Title
Complete response rate (CRR)
Description
The percentage of subjects who achieved complete response
Time Frame
Up to 24 months after C-CAR066 infusion
Title
Duration of response (DOR)
Description
The time from the date of first response (PR or CR) to the date of disease progression or death after C-CAR066 infusion
Time Frame
Up to 24 months after C-CAR066 infusion
Title
Progression free survival (PFS)
Description
The time from C-CAR066 infusion to the date of progression as assessed by Lugano 2014 criteria or death
Time Frame
Up to 24 months after C-CAR066 infusion
Title
Overall survival (OS)
Description
Time from C-CAR066 infusion to death from any cause
Time Frame
Up to 24 months after C-CAR066 infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient volunteered to participate in the study, and signed the Informed Consent Age 18-70 years old, male or female Patients with CD20+ DLBCL (including PMBCL and tFL), FL and MCL, at least one measurable lesion (LDi≥ 1.5 cm) r/r lymphoma patients who received prior CD19 CAR-T therapy At least one week from last treatment (radiation, chemotherapy, mAb, etc) to apheresis No immunosuppressive therapy was used within 1 week before C-CAR066 infusion No mAb treatment within 2 weeks before C-CAR066 infusion Adequate organ and bone marrow function No contraindications of apheresis Expected survival time > 3 months ECOG scores 0-1 Exclusion Criteria: Have a history of allergy to cellular products Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease Patients with active CNS involvement Patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed Live vaccination within 4 weeks before apheresis HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers Have a history of alcoholism, drug addiction and mental illness Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception Patients with severe fludarabine or cyclophosphamide hypersensitivity The patient has a history of other primary cancers, except for the following: Non-melanoma such as skin basal cell carcinoma cured by resection Cured carcinoma in situ such as cervical, bladder or breast cancer The investigators believe that there are other circumstances that are not suitable for the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aibin Liang, MD,Ph.D.
Organizational Affiliation
Shanghai Tongji Hospital, Tongji University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Tongji Hospital, Tongji University School of Medicine
City
Shanghai
ZIP/Postal Code
200065
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

We'll reach out to this number within 24 hrs